12:00 AM
Jul 13, 2015
 |  BioCentury  |  Emerging Company Profile

Monitoring rejections

Transplant Genomics developing blood test to improve kidney transplant outcomes

Transplant Genomics Inc.'s TruGraf blood test could detect problems with kidney transplants earlier than the current methods, and help doctors fine-tune a transplant recipient's immunosuppressive regimen to delay or prevent transplant rejection.

About half of the 17,000 kidney transplants done annually in the U.S. fail within 10 years. For this reason, kidney transplants are routinely monitored for creatinine, a measure of kidney function.

But creatinine is an insensitive, lagging indicator. It does not rise until there is a major problem, and it can be elevated for reasons other than kidney rejection, according to President and CEO Stanley Rose. For example, creatinine is elevated in both acute rejection and acute dysfunction; however, in the latter case, the elevation may be caused by immunosuppression-induced nephrotoxicity.

Biopsies are the gold standard for monitoring kidney transplants, and for-cause biopsies are generally done when creatinine is elevated. About 40% of transplant centers conduct "protocol" biopsies according to a surveillance schedule. This practice...

Read the full 796 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >